Pranoprofen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pranoprofen
Accession Number
DB13514
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
2R7O1ET613
CAS number
52549-17-4
Weight
Average: 255.2686
Monoisotopic: 255.089543287
Chemical Formula
C15H13NO3
InChI Key
TVQZAMVBTVNYLA-UHFFFAOYSA-N
InChI
InChI=1S/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)
IUPAC Name
2-{5H-chromeno[2,3-b]pyridin-7-yl}propanoic acid
SMILES
CC(C(O)=O)C1=CC2=C(OC3=C(C2)C=CC=N3)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabPranoprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololPranoprofen may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pranoprofen.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPranoprofen may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pranoprofen.Approved, Vet Approved
AclarubicinPranoprofen may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pranoprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pranoprofen.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Aldosterone.Experimental, Investigational
AldoxorubicinPranoprofen may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Alendronic acid.Approved
AliskirenPranoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pranoprofen.Experimental
AlprenololPranoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pranoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Amcinonide.Approved
AmikacinPranoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmiloridePranoprofen may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinPranoprofen may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodPranoprofen may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pranoprofen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pranoprofen.Investigational
AnnamycinPranoprofen may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pranoprofen.Approved
Antithrombin III humanPranoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPranoprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Pranoprofen.Investigational
ApramycinPranoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Pranoprofen.Approved, Investigational
ArbekacinPranoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPranoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPranoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPranoprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Atamestane.Investigational
AtenololPranoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pranoprofen.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pranoprofen.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pranoprofen.Approved
BalsalazidePranoprofen may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminPranoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololPranoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPranoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pranoprofen.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Pranoprofen.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pranoprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pranoprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pranoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololPranoprofen may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Pranoprofen.Approved, Investigational
BevantololPranoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pranoprofen.Approved, Investigational
BisoprololPranoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPranoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPranoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pranoprofen.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pranoprofen.Investigational
BucindololPranoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pranoprofen.Experimental
BufuralolPranoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Pranoprofen.Experimental
BumetanidePranoprofen may decrease the diuretic activities of Bumetanide.Approved
BupranololPranoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pranoprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Pranoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pranoprofen.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pranoprofen.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pranoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pranoprofen.Approved, Vet Approved, Withdrawn
CarteololPranoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPranoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pranoprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pranoprofen.Approved, Investigational
CeliprololPranoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinPranoprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pranoprofen.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pranoprofen.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pranoprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pranoprofen.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pranoprofen.Approved
CinoxacinPranoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidPranoprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Pranoprofen.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pranoprofen.Vet Approved
CloranololPranoprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pranoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Pranoprofen.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Pranoprofen.Experimental
CyclosporinePranoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilatePranoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPranoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPranoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanPranoprofen may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinPranoprofen may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Pranoprofen.Experimental
DesirudinPranoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pranoprofen.Approved, Investigational
DextranPranoprofen may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Pranoprofen may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Pranoprofen may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Pranoprofen may increase the anticoagulant activities of Dextran 75.Approved
DibekacinPranoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pranoprofen.Approved, Vet Approved
DicoumarolPranoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Pranoprofen.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pranoprofen.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pranoprofen.Approved
DihydrostreptomycinPranoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Pranoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pranoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pranoprofen.Approved
DoxorubicinPranoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenonePranoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Pranoprofen.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pranoprofen.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Pranoprofen.Investigational
Edetic AcidPranoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPranoprofen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pranoprofen.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pranoprofen.Approved
EnoxacinPranoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPranoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Pranoprofen.Experimental
EpanololPranoprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Pranoprofen.Approved
EpirubicinPranoprofen may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenonePranoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pranoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pranoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Equilin.Approved
EsmololPranoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Estrone sulfate.Approved
Etacrynic acidPranoprofen may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pranoprofen.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetatePranoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pranoprofen.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pranoprofen.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pranoprofen.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pranoprofen.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Pranoprofen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Pranoprofen.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pranoprofen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pranoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Pranoprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pranoprofen.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Pranoprofen.Experimental
Ferulic acidPranoprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pranoprofen.Approved, Investigational
FleroxacinPranoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pranoprofen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fludrocortisone.Approved
FluindionePranoprofen may increase the anticoagulant activities of Fluindione.Investigational
FlumequinePranoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Pranoprofen.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Pranoprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Pranoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pranoprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pranoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxPranoprofen may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumPranoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pranoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pranoprofen.Approved
FramycetinPranoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemidePranoprofen may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexatePranoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPranoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPranoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pranoprofen.Approved, Withdrawn
GemifloxacinPranoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPranoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinPranoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APranoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Pranoprofen may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinPranoprofen may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Pranoprofen is combined with HE3286.Investigational
HeparinPranoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Pranoprofen.Investigational
HydralazinePranoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pranoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pranoprofen.Approved, Investigational
Hygromycin BPranoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pranoprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Pranoprofen.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Pranoprofen.Approved
IdarubicinPranoprofen may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxPranoprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pranoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pranoprofen.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pranoprofen.Approved
IndenololPranoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pranoprofen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pranoprofen.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pranoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pranoprofen.Approved, Investigational
IsepamicinPranoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pranoprofen.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Istaroxime.Investigational
KanamycinPranoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pranoprofen.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pranoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pranoprofen.Approved
LabetalolPranoprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololPranoprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Pranoprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Pranoprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Pranoprofen.Approved, Investigational
LepirudinPranoprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPranoprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololPranoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPranoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Pranoprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pranoprofen.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pranoprofen.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Pranoprofen.Approved
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Pranoprofen.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pranoprofen.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pranoprofen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pranoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pranoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pranoprofen.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Pranoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pranoprofen.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pranoprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Pranoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pranoprofen.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pranoprofen.Approved
MelagatranPranoprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pranoprofen.Approved, Vet Approved
MepindololPranoprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazinePranoprofen may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pranoprofen.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pranoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pranoprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololPranoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pranoprofen.Approved
MetoprololPranoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamidePranoprofen may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinPranoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pranoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pranoprofen.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pranoprofen.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pranoprofen.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pranoprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pranoprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pranoprofen.Approved
NadololPranoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPranoprofen may increase the anticoagulant activities of Nadroparin.Approved
NafamostatPranoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pranoprofen.Approved
Nalidixic AcidPranoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pranoprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Pranoprofen is combined with NCX 1022.Investigational
NeaminePranoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPranoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinPranoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinPranoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pranoprofen.Approved
NetilmicinPranoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Pranoprofen.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pranoprofen.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pranoprofen.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pranoprofen.Investigational
NorfloxacinPranoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pranoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pranoprofen.Approved
OlsalazinePranoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Pranoprofen is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pranoprofen.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Pranoprofen.Vet Approved
OtamixabanPranoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pranoprofen.Approved
Oxolinic acidPranoprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPranoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pranoprofen.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pranoprofen.Approved
ParomomycinPranoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Pranoprofen.Investigational
PazufloxacinPranoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPranoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPranoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePranoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePranoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pranoprofen.Approved
PhenindionePranoprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPranoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pranoprofen.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pranoprofen.Approved, Investigational
PindololPranoprofen may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidPranoprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinPranoprofen may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanidePranoprofen may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pranoprofen.Approved, Investigational
Piromidic acidPranoprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pranoprofen.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pirprofen.Experimental
Platelet Activating FactorPranoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPranoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinPranoprofen may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pranoprofen.Approved
PractololPranoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Pranoprofen.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Pranoprofen can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pranoprofen.Approved, Investigational
PropranololPranoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Pranoprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Pranoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Pranoprofen.Vet Approved
Protein CPranoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanPranoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePranoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPranoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Pranoprofen.Investigational
PuromycinPranoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pranoprofen.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pranoprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pranoprofen.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pranoprofen.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pranoprofen.Approved, Experimental, Investigational
ReviparinPranoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPranoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanPranoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pranoprofen.Investigational, Withdrawn
RosoxacinPranoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinPranoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinPranoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Pranoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pranoprofen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pranoprofen.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pranoprofen.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pranoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pranoprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Pranoprofen.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Pranoprofen.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pranoprofen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pranoprofen.Investigational
SisomicinPranoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPranoprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Pranoprofen.Approved
SotalolPranoprofen may decrease the antihypertensive activities of Sotalol.Approved
SP1049CPranoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinPranoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinPranoprofen may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pranoprofen.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Pranoprofen.Investigational
StreptomycinPranoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinPranoprofen may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pranoprofen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pranoprofen.Approved
SulodexidePranoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Pranoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pranoprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Pranoprofen.Experimental
TacrolimusPranoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Pranoprofen.Approved
TalinololPranoprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pranoprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pranoprofen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pranoprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pranoprofen.Approved, Investigational
TemafloxacinPranoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pranoprofen.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Pranoprofen.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pranoprofen.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Pranoprofen.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pranoprofen.Approved
TertatololPranoprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pranoprofen.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPranoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pranoprofen.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinPranoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pranoprofen.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pranoprofen.Approved
TorasemidePranoprofen may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pranoprofen.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pranoprofen.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pranoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pranoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamterenePranoprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pranoprofen.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pranoprofen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Pranoprofen.Investigational
TrovafloxacinPranoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPranoprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Pranoprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pranoprofen.Investigational, Withdrawn
ValrubicinPranoprofen may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pranoprofen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pranoprofen.Approved
WarfarinPranoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPranoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pranoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pranoprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Pranoprofen.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pranoprofen.Withdrawn
Zoptarelin doxorubicinPranoprofen may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinPranoprofen may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041996
ChemSpider
4719
BindingDB
50286819
ChEBI
32040
ChEMBL
CHEMBL367463
ATC Codes
S01BC09 — Pranoprofen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableRecruitingNot AvailableKeratitis, Herpetic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.03 mg/mLALOGPS
logP2.54ALOGPS
logP2.94ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)3.63ChemAxon
pKa (Strongest Basic)2.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.42 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity70.02 m3·mol-1ChemAxon
Polarizability26.86 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-1290000000-d70f1e7dd20d79171ae0

Taxonomy

Description
This compound belongs to the class of organic compounds known as chromeno[2,3-b]pyridines. These are aromatic heteropolycyclic compounds containing pyridine linearly fused to the pyran moiety of a benzofuran ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
Chromeno[2,3-b]pyridines
Alternative Parents
Diarylethers / Pyranopyridines / Pyridines and derivatives / Benzenoids / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Chromeno[2,3-b]pyridine / Diaryl ether / Pyranopyridine / Pyridine / Benzenoid / Heteroaromatic compound / Carboxylic acid derivative / Carboxylic acid / Ether / Monocarboxylic acid or derivatives
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:43 / Updated on January 19, 2018 10:59